Portal de Periódicos da CAPES

Stop press

1999; Elsevier BV; Volume: 1999; Issue: 48 Linguagem: Inglês

10.1016/1359-6128(99)90471-8

1873-1651

Asthma and respiratory diseases

For patients whose asthma is not adequately controlled with inhaled corticosteroid (ICS) therapy alone, increasing the dose of ICS or the addition of a long-acting β2-agonist is recommended. Greater improvements in lung function are achieved with the addition of a long-acting β2-agonist to ICS therapy, rather than doubling the dose of ICS. Formoterol and salmeterol have a similarly long duration of effect (up to 12 h). However, as a result of their different chemical structures, there are marked pharmacological differences in the mechanism of action which affect their speeds of onset. These differences amount to a more rapid onset of effect for formoterol compared with salmeterol. Long-acting β2-agonists appear to be well tolerated at elevated doses. These two features (tolerability at high doses and rapid onset of effect) support the use of formoterol as a reliever medication in addition to use in maintenance therapy. The long-acting β2-agonists can be considered as beneficial additions to ICS therapy for the management of moderate-to-severe asthma.